Key regions: United Kingdom, Germany, France, South Korea, Italy
The COVID-19 pandemic has had a significant impact on the global economy, including the pharmaceutical industry. One of the most significant developments in this industry has been the emergence of COVID-19 vaccines. France, like many other countries, has been actively involved in the development and distribution of these vaccines.
Customer preferences: In France, there is a high demand for COVID-19 vaccines, with many people eager to get vaccinated as soon as possible. This demand is driven by a desire to protect oneself and others from the virus and to return to a sense of normalcy. Additionally, there is a high level of trust in the medical community and the government, which has led to a willingness to receive the vaccine.
Trends in the market: One of the most significant trends in the COVID-19 vaccine market in France is the increasing availability of vaccines. As more vaccines are approved and produced, there is a greater supply available to the public. Additionally, there has been a shift in the types of vaccines being used, with more emphasis on mRNA vaccines like Pfizer and Moderna. This shift is driven by the higher efficacy rates of these vaccines compared to others, as well as their ability to be rapidly produced and distributed.
Local special circumstances: One unique aspect of the COVID-19 vaccine market in France is the role of the government in distribution. The French government has been actively involved in securing and distributing vaccines, with a focus on ensuring that vulnerable populations are prioritized. Additionally, there has been a push to ensure that vaccines are distributed equitably across the country, with a focus on reaching rural and underserved areas.
Underlying macroeconomic factors: The COVID-19 pandemic has had a significant impact on the French economy, with many businesses and industries struggling to stay afloat. However, the pharmaceutical industry has seen a significant boost in demand due to the pandemic, including the development and distribution of COVID-19 vaccines. Additionally, the French government has invested heavily in vaccine development and distribution, providing a significant boost to the industry. Overall, the COVID-19 vaccine market in France is expected to continue to grow as more vaccines become available and distribution efforts continue.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
